Przejdź do zawartości
Merck

Reversal of target-specific oral anticoagulants.

Drug discovery today (2014-06-01)
Deborah M Siegal, Adam Cuker
ABSTRAKT

Target-specific oral anticoagulants (TSOACs) provide safe and effective anticoagulation for the prevention and treatment of thrombosis in a variety of clinical settings by interfering with the activity of thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban, edoxaban, betrixaban). Although TSOACs have practical advantages over vitamin K antagonists (VKAs), there are currently no antidotes to reverse their anticoagulant effect. Herein we summarize the available evidence for TSOAC reversal using nonspecific and specific reversal agents. We discuss important limitations of existing evidence, which is derived from studies in human volunteers, animal models and in vitro experiments. Studies evaluating the safety and efficacy of reversal agents on clinical outcomes such as bleeding and mortality in patients with TSOAC-associated bleeding are needed.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
Betrixaban, ≥98% (HPLC)